CSL
Develops and delivers biotherapies and vaccines
Manager Operational Excellence
At least four days per week on-site at the Marburg plant.
About the job
- A completed Bachelor of Science degree, for example in industrial engineering or business informatics.
- Advanced knowledge of process and project management, especially the business processes within the area of responsibility.
- Advanced knowledge of Lean and Six Sigma.
- Very good change-management knowledge.
- Good to very good English skills at Level 2 and fluent German skills are essential.
- More than five years of professional experience.
- Strong coaching and facilitation skills, including the ability to engage leaders and interdisciplinary teams in change.
- Strong analytical and conceptual abilities combined with a high implementation focus and pragmatic problem-solving ability.
- Confident communication and persuasive presentation skills across different organizational levels.
- Ability to lead effectively without direct authority, connect stakeholders, and facilitate sustainable decisions.
- Proficiency with Microsoft Office applications.
- Plan, facilitate, and coach COS rollouts in operational areas and support functions.
- Develop, implement, and continuously improve the operational-excellence roadmap for assigned value streams or functions.
- Conduct workshops and enable teams to apply COS elements such as Process Centric Teams, Visual Management, Standard Work, and Leader Standard Work.
- Establish Tier meetings, visual management systems, and continuous-improvement routines and align them with site business priorities.
- Help further develop and train Team Assurance.
- Conduct COS maturity assessments, make progress transparent, and derive targeted improvement measures.
- Analyze operational and administrative processes along the value chain using Value Stream Mapping and identify opportunities for compliance, cost-effectiveness, quality, and efficiency.
- Lead or coach complex cross-functional and, when needed, cross-site continuous-improvement projects and structured problem-solving workshops.
- Apply Lean and Lean Six Sigma methods in practice, including Gemba, 5S, Visual Management, Standard Work, process confirmation, and data-based root-cause analysis.
- Develop solutions and robust recommendations with specialist departments for critical process deviations.
- Coordinate and prioritize a portfolio of improvement initiatives and oversee their implementation and sustainable benefits.
- Prepare and present results, decision options, and progress appropriately for relevant decision-making committees.
- Coach and mentor leaders and teams across multiple organizational levels in Lean Leadership and continuous improvement.
- Embed Leader Standard Work sustainably through Gemba walks, tiered coaching, and regular process confirmation.
- Design, develop, and deliver local and global training and qualification formats covering COS, Lean, Six Sigma, continuous improvement, and structured problem solving.
- Develop change-management and communication concepts and guide employees and leaders through transformation and cultural change.
- Share and further develop good practices and standards within the site and the global operational-excellence network.
- Knowledge of data-analysis and visualization tools such as Minitab or Power BI.
- Knowledge of digital improvement approaches.
About the company
CSL is a global biotechnology company that develops and delivers biotherapies and influenza vaccines. It focuses on plasma-derived and recombinant therapies for rare and serious diseases and sells to healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. Its product range includes treatments for rare diseases, influenza vaccines, and antivenoms, produced through its R&D, manufacturing, and distribution operations. CSL differentiates itself by offering the broadest portfolio of plasma-derived and recombinant therapies and by leveraging its global footprint and emphasis on diversity to reach diverse markets. The company’s main goal is to save lives and protect health by expanding access to high-quality therapies and vaccines worldwide.
Company Size
10,001+
Company Stage
IPO
Headquarters
Parkville, Australia
Founded
1916
Get referred to CSL
See people who can refer or advise you
Simplify's Take
What believers are saying
- CSL realized US$176 million FY26 cost savings, above target, improving margins.
- September 10, 2026 Lancet data strengthens AUJEMFLU's case with older adults and regulators.
- CSL's VarmX collaboration funds Phase 3 VMX-C001, expanding into urgent-surgery anticoagulation reversal.
What critics are saying
- FY26 reported a US$2.6 billion loss after US$7.1 billion impairments and restructuring.
- Pentagon's April 2026 flu mandate repeal cuts Seqirus demand from a major buyer.
- CSL reported March 2026 temporary global HEMGENIX availability issues, risking treatment continuity and trust.
What makes CSL unique
- CSL's FY26 portfolio spans plasma, gene therapy, and leading influenza vaccines.
- HEMGENIX posted 25% FY26 growth, sustaining durable haemophilia B demand.
- AUJEMFLU won MHRA and European Commission approval, plus Lancet superiority data.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Time Off
Paid Vacation
Paid Sick Leave
Paid Holidays
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 2%CSL Seqirus has published Phase 3 study results in The Lancet Infectious Diseases for its MF59-adjuvanted cell-based higher-dose quadrivalent influenza vaccine for older adults. The vaccine, marketed as AUJEMFLU, combines three proven approaches: MF59 adjuvant, cell-based manufacturing, and higher-dose formulation. The randomised study enrolled 7,699 adults aged 50 and older across eight countries. Results demonstrated superiority versus an adjuvanted egg-based comparator across all four influenza strains and age groups. The vaccine showed non-inferiority versus a recombinant vaccine for three of four strains in the 50-plus age group and all four strains in those aged 65-plus. The trivalent formulation received approval from the UK's MHRA and the European Commission earlier this year for adults aged 50 and above. Regulatory submissions have been made in multiple markets.
Australian biopharmaceutical company CSL reported a 2% decline in annual profit on Tuesday, as its core plasma division experienced falling revenue. The company posted an underlying net profit after tax of $3.14 billion on a constant currency basis for the year ended 30 June, down from $3.22 billion the previous year. CSL is among the world's leading flu vaccine manufacturers. The results reflect challenges in the plasma business, which forms a significant part of the company's operations.
CSL has announced a restructuring plan including the separation of its Seqirus influenza vaccine business into a standalone entity, alongside workforce reductions and plasma collection centre closures. Management cited prolonged margin pressures and operational challenges as drivers for the changes. The announcement follows a sharp share price decline, with CSL trading at A$124.84, down 27.4% year-to-date and 50.1% over the past year. Three-year and five-year returns show declines of 56.3% and 51.0% respectively. The restructuring aims to simplify operations and refocus capital on higher-returning areas. Separating Seqirus could provide clearer visibility into CSL's core plasma and specialty therapies businesses, whilst allowing independent capital allocation decisions. However, investors face execution risks typical of separations of this scale, including one-off charges and operational disruption.
Australian biotech CSL extended losses on Thursday, falling to its lowest level since August 2017, after the US Pentagon scrapped its flu vaccine mandate for military personnel. The stock dropped as much as 0.8%, bringing yearly losses to over 25%. The policy reversal threatens demand from a key institutional buyer, compounding CSL's existing challenges. The company's Seqirus vaccines unit generated $2.17 billion in revenue in fiscal 2025, representing 14% of total revenue. CSL has faced sustained pressure from slowing demand for plasma-derived therapies, higher costs and multiple earnings downgrades. The stock plunged 39% last year, its biggest annual drop since 2002. Analysts cite concerns over falling US flu vaccination rates, weaker Seqirus earnings and delayed strategic plans.
In a high-stakes move that could reshape emergency medicine, global biotech giant CSL has struck an exclusive option agreement to acquire VarmX, a Netherlands-based biotech, in a deal valued at up to $2.2 billion. The announcement, made Tuesday by EQT Life Sciences, which counts VarmX in its portfolio, underscores just how valuable the Dutch company’s CSL to acquire VarmX in a $2.2B deal, backing breakthrough bleeding drug VMX-C001 with full trial funding.